Paclitaxel and TRAIL Synergize to Kill Paclitaxel-resistant Small Cell Lung Cancer Cells through a Caspase-independent Mechanism Mediated through AIF

BACKGROUND: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with poor disease outcome. Chemotherapeutic agent paclitaxel (PA) is commonly used as a second-line treatment in SCLC, but response rates are low. MATERIALS AND METHODS: 86M1 SCLC cells were treated in the presence...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Anticancer Res
Hlavní autoři: HUNTER, TERRI B., MANIMALA, NEIL J., LUDDY, KIMBERLY A., CATLIN, TRACY, ANTONIA, SCOTT J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4241353/
https://ncbi.nlm.nih.gov/pubmed/21965726
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky